Defects in the apoptotic machinery of cancer cells: Role in drug resistance

Seminars in Cancer Biology

Volumn 13, Issue 2, 2003, Pages 125-134

  Zhivotovsky, Boris ^a   Orrenius, Sten ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Cancer; Sensitivity; Treatment

Indexed keywords

PROTEIN; RECEPTOR;

APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL ASSAY; CELL KILLING; ENZYME ACTIVATION; MITOCHONDRION; REGULATORY MECHANISM; REVIEW; TUMOR CELL;

ANIMALS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 0037377102     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00130-X     Document Type: Review

References (82)

1. Hanagan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
2. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:2002;153-164.
3. Igney F.H., Krammer P.H. Death and anti-death: tumor resistance to apoptosis. Nat. Rev. Cancer. 2:2002;277-288.
4. Ashkenazi A. Targeting death and decoy receptors of the tumour-nectosis factor superfamily. Nat. Rev. Cancer. 2:2002;420-430.
5. Karin M., Lin A. NF-kB at the crossroads of life and death. Nat. Immunol. 3:2002;221-227.
6. Kaufmann S.H., Hengartner M.O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 11:2001;526-534.
7. Robertson J., Enoksson M., Suomela M., Zhivotovsky B., Orrenius S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J. Biol. Chem. 277:2002;29803-29809.
8. Lassus P., Opitz-Araya X., Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science. 297:2002;1352-1354.
9. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer. 2:2002;594-604.
10. Nicholson D.W. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6:1999;1028-1042.
11. Li X., Yang Y., Ashwell J.D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature. 416:2002;345-347.
12. Verhagen A.M., Coulson E.J., Vaux D.L. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2:2001;3009.1-3009.10.
13. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102:2000;33-42.
14. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E.et al. Identification of DIABLO a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 102:2000;43-53.
15. Okada H., Suh W.K., Jin J., Woo M., Du C., Elia A.et al. Generation and characterization of Smac/DIABLO-deficient mice. Mol. Cell Biol. 22:2002;3509-3517.
16. Jäättelä M. Escaping cell death: survivial proteins in cancer. Exp. Cell Res. 248:1999;30-43.
17. Garrido C., Gurbuxani S., Ravagnan L., Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem. Biophys. Res. Commun. 286:2001;433-442.
18. Mathiasen I.S., Jäättelä M. Triggering caspase-independent cell death to combat cancer. Trends Mol. Med. 8:2002;212-220.
19. Cande C., Cohen I., Daugas E., Ravagnan L., Larochette N., Zamzami N.et al. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie. 84:2002;215-222.
20. Friesen C., Fulda S., Debatin K.M. Cytotoxic drugs and the CD-95 pathway. Leukemia. 13:1999;1854-1858.
21. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement, of the CD-95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2: 574-577.
22. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L.E.et al. Melanoma cell expression of Fas(Apo-1/CD-95) ligand: implications for tumor immune escape. Science. 274:1996;1363-1366.
23. Joseph B., Ekedahl J., Sirzen F., Lewensohn R., Zhivotovsky B. Differences in expression of pro-caspases in small-cell and non-small-cell lung carcinoma. Biochem. Biophys. Res. Commun. 262:1999;381-387.
24. Teitz T., Wei T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A.et al. Caspase-8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6:2000;529-535.
25. Fulda S., Küfer M.U., Meyer E., van Valen F., Dockhorn-Dworniczak B., Debatin K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 20:2001;5865-5877.
26. Mandruzzato S., Brasseur F., Andry G., Boon T., van der Bruggen P. A CASP-8 mutation recognized by cytotoxic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186:1997;785-793.
27. Takita J., Yang H.W., Chen Y.Y., Hanada R., Yamamoto K., Teitz T.et al. Allelic imbalance on chromosome 2q and alterations of the caspase-8 gene in neuroblastoma. Oncogene. 20:2001;4424-4432.
28. Liu B., Peng D., Lu Y., Jin W., Fan Z. A novel single amino acid deletion caspase-8 mutant in cancer cells that lost pro-apoptotic activity. J. Biol. Chem. 277:2002;30159-30164.
29. Shin M.S., Kim H.S., Kang C.S., Park W.S., Kim S.Y., Lee S.N.et al. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood. 99:2002;4094-4099.
30. Hu S., Vincenz C., Ni J., Gentz R., Dixit V.M. I-Flice, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J. Biol. Chem. 272:1997;17255-17257.
31. Irisarri M., Plumas J., Bonnefoix T., Jacob M.C., Roucard C., Pasquier M.A.et al. Resistance to CD-95-mediated apoptosis through constitutive FLIP expression in a non-Hodgkin's lymphoma B cell line. Leukemia. 14:2000;2149-2158.
32. Mitsiades N., Mitsiades C.S., Poulaki V., Anderson K.C., Treon S.P. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 99:2002;2162-2171.
33. Burns T.F., El-Deiry W.S. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem. 276:2001;37879-37886.
34. Olsson A., Diaz T., Aguilar-Santelies M., Osterborg A., Celsing F., Jondal M.et al. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia. 15:2001;1868-1877.
35. Daniel P.T., Wieder T., Sturm I., Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia. 15:2001;1022-1031.
36. Blagosklonny M.V. Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? Bioessay. 23:2001;947-953.
37. Coutlas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 2003;13:115-123.
38. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15:1999;269-290.
39. Cecconi F., Alvarez-Bolado G., Meyer B.I., Roth K.A., Gruss P. Apaf-1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell. 94:1998;727-737.
40. Soengas M.S., Alarcon R.M., Yoshida H., Giaccia A.J., Hakem R., Mak T.W.et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 284:1999;156-159.
41. Fearnhead H.O., Rodriguez J., Govek E.E., Guo W., Kobayashi R., Hannon G.et al. Oncogene-dependent apoptosis is mediated by caspase-9. Proc. Natl. Acad. Sci. USA. 95:1998;13664-13669.
42. Perkins C., Kim C.N., Fang G., Bhalla K. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res. 58:1998;4561-4566.
43. Jia L., Srinivasula M., Liu F.T., Newland A.C., Fernandes-Alnemri T., Alnemri E.S.et al. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood. 98:2001;414-421.
44. Wolf B.B., Schuler M., Li W., Eggers-Sedlet B., Lee W., Tailor P.et al. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J. Biol. Chem. 276:2001;34244-34251.
45. Soengas M.S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X.et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 409:2001;207-211.
46. Moroni M.C., Hickman E.S., Denchi E.L., Caprara G., Colli E., Cecconi F.et al. Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell Biol. 3:2001;552-558.
47. Bouchier-Hayes L., Martin S.J. CARD games in apoptosis and immunity. EMBO Rep. 3:2002;616-621.
48. Seol D.W., Billiar T.R. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J. Biol. Chem. 274:1999;2072-2076.
49. Srinivasula S.M., Ahmad M., Guo Y., Zhan Y., Lazebnik Y., Fernandes-Alnemri T.et al. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Res. 59:1999;999-1002.
50. Liu J.R., Opopari A.W., Tan L., Jiang Y., Zhang Y., Tang H.et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res. 62:2002;924-931.
51. Svingen P.A., Karp J.E., Krajewski S., Mesner P.W. Jr., Gore S.D., Burke P.J.et al. Evaluation of Apaf-1 and pro-caspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood. 96:2000;3922-3931.
52. Teitz T., Wei T., Liu D., Valentine V., Valentine M., Grenet J.et al. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Oncogene. 21:1992;1848-1858.
53. Shinoura N., Sakurai S., Asai A., Kirono T., Hamada H. Co-transduction of Apaf-1 and caspase-9 augments etoposide-induced apoptosis in U-373MG glioma cells. Jpn. J. Cancer Res. 92:2001;467-474.
54. Ferreira C.G., van der Valk P., Span S.W., Ludwig I., Smit E.F., Kruyt F.A.et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small-cell lung cancer patients. Clin. Cancer Res. 7:2001;2468-2474.
55. Ekedahl J., Joseph B., Grigoriev M.Y., Müller M., Magnusson C., Lewensohn R.et al. Expression of inhibitor of apoptosis proteins in small-and non-small-cell lung carcinoma cells. Exp. Cell Res. 279:2002;277-290.
56. Liu S.S., Tsang B.K., Cheung A.N., Xue W.C., Cheng D.K., Ng T.Y.et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur. J. Cancer. 37:2001;1104-1110.
57. Tamm I., Kornblau S.M., Segall H., Krajewski S., Welsh K., Kitada S.et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6:2000;1796-1803.
58. Ferreira C.G., van der Valk P., Span S.W., Jonker J.M., Postmus P.E., Kruyt F.A.et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann. Oncol. 12:2001;799-805.
59. Harlin H., Reffey S.B., Duckett C.S., Lindsten T., Thompson C.B. Characterization of xiap-deficient mice. Mol. Cell Biol. 21:2001;3604-3608.
60. Grossman D., Altieri D.C. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metast. Rev. 20:2001;3-11.
61. Guo F., Nimmanapali R., Paranawithana S., Wittman S., Griffin D., Bali P.et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood. 99:2002;3419-3426.
62. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vitro. Nat. Med. 8:2002;808-815.
63. Vucic D., Deshayes K., Ackerly H., Pisabarro M.T., Kadkhodayan S., Fairbrother W.J.et al. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J. Biol. Chem. 277:2002;12275-12279.
64. Roberts D.L., Merrison W., MacFarlane M., Cohen G.M. The inhibitor of apoptosis protein-binding domain of Smac is not essential for its pro-apoptotic activity. J. Cell Biol. 153:2001;221-228.
65. Chauhan D., Hideshima T., Rosen S., Reed J.C., Kharbanda S., Anderso K.C. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 276:2001;24453-24456.
66. Suzuki Y., Imai Y., Nakayama H., Takahashi K., Takio K., Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell. 8:2001;613-621.
67. Liang Y., Yan C., Schor N.F. Apoptosis in the absence of caspase-3. Oncogene. 20:2001;6570-6578.
68. Tetnev T., Marani M., McNeish I., Lemoine N.R. Pro-caspase-3 overexpression sensitizes ovarian cancer cells to proteasome inhibitors. Cell Death Differ. 8:2001;256-264.
69. Yang X.H., Sladek T.L., Liu X., Butler B.R., Froelich C.J., Thor A.D. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res. 61:2001;348-354.
70. Winter R.N., Kramer A., Borkowski A., Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 61:2001;1227-1232.
71. Faderl S., Thall P.F., Kantarjian H.M., Talpaz M., Harris D., Van Q.et al. Caspase-2 and caspase-3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin. Cancer Res. 5:1999;4041-4047.
72. Joseph B., Ekedahl J., Lewensohn R., Marchetti P., Formstecher P., Zhivotovsky B. Defective caspase-3 relocalization in non-small-cell lung carcinoma. Oncogene. 20:2001;2877-2888.
73. Kottke T.J., Blajeski A.L., Meng X.W., Svingen P.A., Ruchaud S., Mesner P.W. Jr.et al. Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells. J. Biol. Chem. 277:2002;804-815.
74. Kawabata Y., Hirokawa M., Kitabayashi A., Horiuchi T., Kuroki J., Miura A.B. Defective apoptotic signal transduction pathway downstream of caspase-3 in human B-lymphoma cells: a novel mechanism of nuclear apoptosis resistance. Blood. 94:1999;3523-3530.
75. DeChant A.K., Dee K., Weyman C.M. Raf-induced effects on the differentiation and apoptosis of skeletal myoblasts are determined by the level of Raf signaling: abrogation of apoptosis by Raf is downstream of caspase-3 activation. Oncogene. 21:2002;5268-5279.
76. Joseph B., Marchetti P., Formstecher P., Kroemer G., Lewensohn R., Zhivotovsky B. Mitochondrial dysfunction is an essential step for killing of non-small-cell lung carcinomas resistant to conventional treatment. Oncogene. 21:2002;65-77.
77. Leist M., Jäättelä M. Triggering of apoptosis by cathepsins. Cell Death Differ. 8:2001;324-326.
78. Zhu D.M., Uckun F.M. Cathepsin inhibition induces apoptotic death in human leukemia and lymphoma cells. Leuk Lymphoma. 39:2000;343-354.
79. Girnita L., Girnita A., Brodin B., Xie Y., Nilsson G., Dricu A.et al. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 60:2000;5278-5283.
80. Sperandio S., de Belle I., Bredesen D.E. An alternative nonapoptotic form of programmed cell death. Proc. Natl. Acad. Sci. USA. 97:2000;14376-14381.
81. Reiss K., Yumet G., Shan S., Huang Z., Alnemri E., Srinivasula S.M.et al. Synthetic peptide sequence from the C-terminus of the insulin-like growth factor-I receptor that induces apoptosis and inhibition of tumor growth. J. Cell Physiol. 181:1999;124-135.
82. Chandra J., Mansson E., Gogvadze V., Kaufmann S.H., Albertioni F., Orrenius S. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Blood. 99:2002;655-663.